We revised our 142 CML patients' samples in light of the transcript variants. Indeed, a difference was appreciable considering all the 512 samples collected throughout the duration of the study and evaluating the detectability of BCR-ABL1 by qPCR. e13a2 samples presented a higher rate (115/205) of detection compared with e14a2 ones (144/307; P = 0.0367). No difference was appreciable in terms of dPCR quantification, neither for fluorescence intensity, as considered by Kjaer et al, nor for absolute level of transcript

Variant-specific discrepancy when quantitating {BCR}-{ABL}1 e13a2 and e14a2 transcripts using the Europe Against Cancer {qPCR} assay. Is {dPCR} the key?

Massimiliano Bonifacio;
2019

Abstract

We revised our 142 CML patients' samples in light of the transcript variants. Indeed, a difference was appreciable considering all the 512 samples collected throughout the duration of the study and evaluating the detectability of BCR-ABL1 by qPCR. e13a2 samples presented a higher rate (115/205) of detection compared with e14a2 ones (144/307; P = 0.0367). No difference was appreciable in terms of dPCR quantification, neither for fluorescence intensity, as considered by Kjaer et al, nor for absolute level of transcript
Europe
Fusion Proteins, bcr-abl
Humans
Imatinib Mesylate
Real-Time Polymerase Chain Reaction
Neoplasms
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11562/1049481
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 12
social impact